These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

94 related articles for article (PubMed ID: 4317029)

  • 1. [The course and results of treatment of pulmonary tuberculosis as a function of the dosage of Pyrazinamide].
    Malinowska B; Pawlak F
    Gruzlica; 1970; 38(6):531-5. PubMed ID: 4317029
    [No Abstract]   [Full Text] [Related]  

  • 2. [Treatment of drug resistant chronic pulmonary tuberculosis with a number of tuberculostatics].
    Bernard E
    Bull Int Union Tuberc; 1968 Dec; 41():183-7. PubMed ID: 4303862
    [No Abstract]   [Full Text] [Related]  

  • 3. A comparison of regimens of ethionamide, pyrazinamide and cycloserine in re-treatment of patients with pulmonary tuberculosis.
    Bignall JR
    Bull Int Union Tuberc; 1968 Dec; 41():175-7. PubMed ID: 4885379
    [No Abstract]   [Full Text] [Related]  

  • 4. Treatment of patients with drug-resistance in economically developed countries.
    Crofton J
    Tubercle; 1969 Mar; 50():Suppl:65-8. PubMed ID: 4319134
    [No Abstract]   [Full Text] [Related]  

  • 5. Ethambytol in the retreatment of pulmonary tuberculosis. United States Public Health Service cooperative trial.
    Steininger WJ
    Bull Int Union Tuberc; 1968 Dec; 41():181-2. PubMed ID: 4303861
    [No Abstract]   [Full Text] [Related]  

  • 6. Cycloserine plus ethionamide plus pyrazinamide in the treatment of patients excreting isoniazid-resistant tubercle bacilli following previous chemotherapy.
    Ramakrishnan CV; Parthasarathy R; Sambamoorthy S; Somasundaram PR; Subbammal S
    Indian J Med Res; 1976 Jan; 64(1):76-82. PubMed ID: 818010
    [No Abstract]   [Full Text] [Related]  

  • 7. [Pyrazinamide, cycloserine and ethionamide in the complex treatment of pulmonary tuberculosis].
    Aspevik E
    Tidsskr Nor Laegeforen; 1967 Mar; 87(6):548-54. PubMed ID: 6047184
    [No Abstract]   [Full Text] [Related]  

  • 8. The problem of the chronic excretor of tubercle bacilli.
    Stýblo K; Kubík A; Langerová M; Matusková E; Morávková K
    Scand J Respir Dis; 1968; 49(3):236-48. PubMed ID: 4309247
    [No Abstract]   [Full Text] [Related]  

  • 9. [Administration of reserve antitubercular drugs in a single daily dose].
    Bek E; Bukalska Z; Zachara A
    Gruzlica; 1968; 37(1):43-7. PubMed ID: 5720037
    [No Abstract]   [Full Text] [Related]  

  • 10. [Th 13-14 and PZA and CS in the treatment of chronic cavitary tuberculosis with bacterial resistance to classic antibacterial drugs].
    Zunić D
    Tuberkuloza; 1966; 18(5):429-40. PubMed ID: 16296047
    [No Abstract]   [Full Text] [Related]  

  • 11. [Cheotherapy of chronic pulmonary tuberculosis with resistant mycobacteria].
    Fegiz G
    Policlinico Prat; 1967 Oct; 74(43):1454-62. PubMed ID: 5629122
    [No Abstract]   [Full Text] [Related]  

  • 12. [Comparison among single, double and triple drug regimens in retreatment. (the seventh series of the trial, B)].
    Kekkaku; 1968 Jun; 43(6):199-207. PubMed ID: 5701828
    [No Abstract]   [Full Text] [Related]  

  • 13. Ethambutol in the treatment of 26 patients with chronic active pulmonary tuberculosis.
    Jesiotr M
    Tubercle; 1969 Mar; 50():Suppl:54-5. PubMed ID: 4319133
    [No Abstract]   [Full Text] [Related]  

  • 14. A comparison of regimens of ethionamide, pyrazinamide and cycloserine in re-treatment of patients with pulmonary tuberculosis.
    Bignall JR; Lind A; Rist N
    Bull Int Union Tuberc; 1969 Aug; 42():7-57. PubMed ID: 5004884
    [No Abstract]   [Full Text] [Related]  

  • 15. [Clinical effects of rifampicin for pulmonary tuberculosis patients. 2. Results of rifampicin treatment for advanced pulmonary tuberculosis patients resistant to conventional antituberculous drugs].
    Kekkaku; 1971 Nov; 46(11):423-8. PubMed ID: 4335256
    [No Abstract]   [Full Text] [Related]  

  • 16. [Advances and principles in tuberculostatic therapy].
    Bethge H
    Internist (Berl); 1971 Aug; 12(8):328-31. PubMed ID: 4328130
    [No Abstract]   [Full Text] [Related]  

  • 17. [Treatment with secondary antitubercular agents].
    Ovreberg K
    Tidsskr Nor Laegeforen; 1968 May; 88(9):741-9. PubMed ID: 4298856
    [No Abstract]   [Full Text] [Related]  

  • 18. [Effect and toxicity on the combined use of pyrazinamide, ethionamide and kanamycin in the retreatment of pulmonary tuberculosis (author's transl)].
    Zhonghua Jie He He Hu Xi Xi Ji Bing Za Zhi; 1979; 2(4):199-200. PubMed ID: 555425
    [No Abstract]   [Full Text] [Related]  

  • 19. Duration of application and change of a regimen with secondary drugs.
    Oka S; Takase Y; Kato S
    Sci Rep Res Inst Tohoku Univ Med; 1968 Oct; 15(1):46-9. PubMed ID: 4308926
    [No Abstract]   [Full Text] [Related]  

  • 20. [Various biological tests on several groups of subjects with tuberculosis subjected respectively to monotherapy with isoniazid, viomycin, pyrazinamide, cycloserine, ethioniamide and kanamycin].
    DE SIMONI G; CATTANEO C
    Ann Ist Carlo Forlanini; 1962; 22():326-65. PubMed ID: 14026068
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 5.